# US 2021/0261932 A1 · Crispr-cas enzymes with enhanced on-target activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261932 A1
- Document ID: US20210261932A1
- Status: Published application
- Kind: A1
- Application number: 17/157,805
- Filed: 2021-01-25
- Published: 2021-08-26
- Earliest claimed: 2020-01-24
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Benjamin Kleinstiver; Russell T. Walton
- Web page: https://patentgrep.com/patent/US20210261932A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/907: {in mammalian cells}
- C07K 2319/71: containing domain for transcriptional activaation, e.g. VP16
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Engineered versions of Streptococcus pyogenes Cas9 (SpCas9) and SpCas9 variants that have improved on-target editing capabilities, and methods of use thereof.

## Claims

### Claim 1

An isolated Streptococcus pyogenes Cas9 (SpCas9) protein, with mutations at one, two, three, four, five, or more of the positions shown in Table 1, 2, or 3, wherein if only one mutation is present, the mutation is not G1218R; L1111R; A1322R: D1332K; N394K; R221K; L1245V; E1243K; or E1253K.

### Claim 2 (depends on 1)

The isolated protein of claim 1, comprising a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:1.

### Claim 3 (depends on 1, 2)

The isolated protein of claim 1 or 2, comprising at least one of the following mutations: G1104X, preferably G1104K or G1104R; A61X, preferably A61R; N1317X, preferably N1317R; S55X, preferably S55R; T1314X, preferably T1314R; G366X, preferably G366R; A1285X, preferably A1285R or A1285K; D1332X, preferably D1332R or D1332H or D1332Q or D1332N; KI 151X, preferably K1151R; T1138X, preferably T1138K or T1138R; V1139X, preferably V1139T; K1289X, preferably K1289R; A1322X, preferably A1322K; and/or L1111X, preferably L1111K, wherein if only one mutation is present, the mutation is not L1111R, A1322R, or D1332K.

### Claim 4 (depends on 3)

The isolated protein of claim 3, comprising mutations A61R/N1317R, G1104K/N1317R, A61R/G1104K, S55R/G1104K, S55R/A61R, S55R/N1317R, G1104K/T1314R, A61R/T1314R, T1314R/N1317R, S55R/T1314R, A61R/G1104R, G1104R/N1317R, S55R/G1104R, G1104R/T1314R, G366R/G1104K, S55R/G366R, A61R/G366R, G366R/N1317R, G366R/T1314R, G366R/G1104R, G1104K/A1285R, A61R/A1285R, A1285R/N1317R, S55R/A1285R, A1285R/T1314R, G1104R/A1285R, G366R/A1285R, G1104K/A1285K, A61R/A1285K, A1285K/N1317R, S55R/A1285K, A1285K/T1314R, G1104R/A1285K, G366R/A1285K, G1104K/D1332R, A61R/D1332R, D1332R/N1317R, S55R/D1332R, D1332R/T1314R, G1104R/D1332R, G366R/D1332R, A1285K/Dl 332R, A1285R/D1332R, A61R/G1104K/N1317R, A61R/L1111R, A61R/A1322R A61R/L1111R/A1322R, G1104K/L1111R, G1104K/A1322R, G1104K/L1111R/A1322R, N317R/L1111R, N1317R/A1322R, N1317R/L1111R/A1322R, A61R/N1317R/L1111R, A61R/N1317R/A1322R, A61R/N1317R/L1111R/A1322R, G1104K/N1317R/L1111R, G1104K/N1317R/A1322R, G1104K/N1317R/L1111R/A1322R, A61R/G1104K/L1111R, A61R/G1104K/A1322R, A61R/G1104K/L1111R/A1322R, S55R/L1111R, S55R/A1322R, S55R/L1111R/A1322R, G366R/LI 111R, G366R/A1322R, G366R/L11I1R/A1322R, N394K/L1111R N394K/A1322R, N394K/L1111R/A1322R, A1285K/L1111R, A1285K/A1322R, A1285K/L1111R/A1322R, D1332K/L1111R, D1332K/A1322R, or D1332K/L1111R/A1322R.

### Claim 5 (depends on 1)

The isolated protein of claim 1, further comprising one or more mutations that decrease nuclease activity selected from the group consisting of mutations at D10, E762, D839, H983, or D986; and at H840 or N863.

### Claim 6 (depends on 5)

The isolated protein of claim 5, wherein the mutations are:
(i) D10A or D10N, and
(ii) H840A, H840N, or H840Y.

### Claim 7 (depends on 1)

The isolated protein of claim 1, further comprising one or more mutations that increase specificity selected from the group consisting of mutations at N497, R661, N692, M694, Q695, H698, K810, K848, Q926, K1003, R0160, R691, M495, Y515, K526, and/or R661.

### Claim 8 (depends on 7)

The isolated protein of claim 7, further comprising mutations at R691A, M495V, Y515N, K526E, R661Q, R661L, R661S, Y450A/Q695A, L169A/Q695A, Q695A/Q926A, Q695A/D1135E, Q926A/D1135E, Y450A/D1135E, L169A/Y450A/Q695A, L169A/Q695A/Q926A, Y450A/Q695A/Q926A, R661A/Q695A/Q926A, N497A/Q695A/Q926A, Y450A/Q695A/D1135E, Y450A/Q926A/D135E, Q695A/Q926A/D1135E, L169A/Y450A/Q695A/Q926A, L169A/R661A/Q695A/Q926A, Y450A/R661A/Q695A/Q926A, N497A/Q695A/Q926A/D I135E, R661A/Q695A/Q926A/D1135E, and Y450A/Q695A/Q926A/D1135E; N692A/M694A/Q695A/H698A, N692A/M694A/Q695A/H698A/Q926A; N692A/M694A/Q695A/Q926A: N692A/M694A/H698A/Q926A; N692A/Q695A/H698A/Q926A: M694A/Q695A/H698A/Q926A; N692A/Q695A/H698A; N692A/M694A/Q695A; N692A/H698A/Q926A; N692A/M694A/Q926A; N692A/M694A/H698A: M694A/Q695A/H698A; M694A/Q695A/Q926A; Q695A/H698A/Q926A: G582A/V583A/E584A/D585A/N588A/Q926A: G582A/V583A/E584A/D585A/N588A; T657A/G658A/W659A/R661A/Q926A; T657A/G658A/W659A/R661A; F491A/M495A/T496A/N497A/Q926A; F491A/M495A/T496A/N497A; K918A/V922A/R925A/Q926A; or 918A/V922A/R925A; K855A; K810A/K1003A/R1060A; K848A/K1003A/R1060A; M495V/Y515N/K526E/R661Q; M495V/Y515N/K526E/R661L; or M495V/Y515N/K526E/R661S.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A fusion protein comprising the isolated protein of claims 1-8, fused to a heterologous functional domain, with an optional intervening linker, wherein the linker does not interfere with activity of the fusion protein.

### Claim 10 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is a transcriptional activation domain.

### Claim 11 (depends on 10)

The fusion protein of claim 10, wherein the transcriptional activation domain is from VP16, VP64, rTA, NF-κB p65, or the composite VPR (VP64-p65-rTA).

### Claim 12 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is a transcriptional silencer or transcriptional repression domain.

### Claim 13 (depends on 12)

The fusion protein of claim 12, wherein the transcriptional repression domain is a Krueppel-associated box (KRAB) domain, ERF repressor domain (ERD), or mSin3A interaction domain (SID).

### Claim 14 (depends on 12)

The fusion protein of claim 12, wherein the transcriptional silencer is Heterochromatin Protein 1 (HP1).

### Claim 15 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is an enzyme that modifies the methylation state of DNA.

### Claim 16 (depends on 15)

The fusion protein of claim 15, wherein the enzyme that modifies the methylation state of DNA is a DNA methyltransferase (DNMT) or a TET protein.

### Claim 17 (depends on 16)

The fusion protein of claim 16, wherein the TET protein is TET1.

### Claim 18 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is an enzyme that modifies a histone subunit.

### Claim 19 (depends on 18)

The fusion protein of claim 18, wherein the enzyme that modifies a histone subunit is a histone acetyltransferase (HAT), histone deacetylase (HDAC), histone methyltransferase (HMT), or histone demethylase.

### Claim 20 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is a base editor or a prime editor.

### Claim 21 (depends on 20)

The fusion protein of claim 20, wherein the base editor is a DNA or RNA deaminase, preferably a cytosine or adenine deaminase domain, or activation-induced cytidine deaminase; or wherein the prime editor comprises a reverse transcriptase (RT) domain.

### Claim 22 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is a biological tether.

### Claim 23 (depends on 22)

The fusion protein of claim 22, wherein the biological tether is MS2, Csy4 or lambda N protein.

### Claim 24 (depends on 9)

The fusion protein of claim 9, wherein the heterologous functional domain is FokI.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

An isolated nucleic acid encoding the protein of claims 1-24.

### Claim 26 (depends on 25)

A vector comprising the isolated nucleic acid of claim 25.

### Claim 27 (depends on 25, 26)

The vector of claim 26, wherein the isolated nucleic acid of claim 25 is operably linked to one or more regulatory domains for expressing an isolated Streptococcus pyogenes Cas9 (SpCas9) protein, preferably with mutations at one, two or more of the positions shown in Tables 2 or 3.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A host cell, preferably a mammalian host cell, comprising the nucleic acid of claim 25, and optionally expressing the protein of claims 1-24.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of altering the genome of a cell, the method comprising expressing in the cell, or contacting the cell with, the isolated protein or fusion protein of claim 1-24, and a guide RNA having a region complementary to a selected portion of the genome of the cell.

### Claim 30 (depends on 29)

The method of claim 29, wherein the isolated protein or fusion protein comprises one or more of a nuclear localization sequence, cell penetrating peptide sequence, and/or affinity tag.

### Claim 31 (depends on 30)

The method of claim 30, wherein the cell is a stem cell.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cell is an embryonic stem cell, mesenchymal stem cell, or induced pluripotent stem cell; is in a living animal; or is in an embryo.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of altering a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with the isolated protein or fusion protein of claims 1-24, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule.

### Claim 34 (depends on 33)

The method of claim 33, wherein the dsDNA molecule is in vitro.

### Claim 35 (depends on 33)

The method of claim 33, wherein the fusion protein and RNA are in a ribonucleoprotein complex.
